Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Subscribe To Our Newsletter & Stay Updated
